Tumor necrosis factor-related apoptosis-inducing ligand induces cytotoxicity specific to osteosarcoma by microRNA response elements

FEI XIAO, JUWU CHEN, CHUANJU LIAN, PENGCHAO HAN and CHAOYANG ZHANG

Department of Emergency Surgery, The First Affiliated Hospital of Zhengzhou University,
Zhengzhou, Henan 450052, P.R. China

Received February 17, 2014; Accepted September 9, 2014

DOI: 10.3892/mmr.2014.2710

Abstract. As the most common primary bone neoplasm, osteosarcoma is highly aggressive and represents a high risk to human health. Biological agents, including tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), are considered promising therapeutic strategies for osteosarcoma. The current issue limiting the application of TRAIL gene therapy is that normal cells are also affected due to the lack of tumor selectivity. The present study aimed to employ the miRNA response elements (MREs) of microRNA (miR)-34 and miR-122, which are tumor suppressors, to enable the selective expression of TRAIL by adenoviral vectors in osteosarcoma cells. The results revealed that miR-34 and miR-122 were underexpressed in osteosarcoma tissues, compared with normal tissues. The MREs of miR-34 and miR-122 ensured that the luciferase gene was expressed selectively in osteosarcoma cells. Adenovirus (Ad)-TRAIL-34-122, which expressed TRAIL in an miR-34 and miR-122-regulated manner, selectively expressed TRAIL in the osteosarcoma cells assessed, which was detected using reverse transcription quantitative polymerase chain reaction, immunoblotting and ELISA. Apoptosis and cytotoxicity were also detected in the osteosarcoma cells, compared with the normal cells. Animal experiments further indicated that Ad-TRAIL-34-122 was able to reduce the growth of osteosarcoma xenografts without toxicity to the liver. In conclusion, the present study identified a novel miRNA-regulated biological cancer therapy against osteosarcoma, which is tumor selective and may be promising for future clinical treatment.

Introduction

Osteosarcoma is one of the most frequent types of malignant cancer and poses a threat to human health (1). It has been revealed that the aberrant expression of tumor suppressor genes is important in the progression, invasion and metastasis of osteosarcoma (1). Thus, gene therapy is an effective strategy for the treatment of osteosarcoma (2).

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in various cancer cells by binding cellular receptors, death receptor (DR)4 and DR5, and activating the downstream signal transduction pathway (3,4). Adenovirus (Ad)-mediated TRAIL delivery has been well documented to exert antitumor activity against osteosarcoma, both in vitro and in animal models (5,6). Furthermore, the extensive expression of DR4 and DR5 in osteosarcoma ensures that TRAIL may be an effective strategy in future clinical treatment (7).

However, TRAIL has been demonstrated to induce apoptosis in hepatic cells by inducing the FAS-mediated downstream molecular pathway (8). The cytotoxicity of TRAIL to normal liver cells impedes its clinical application in the treatment of osteosarcoma. Therefore, a novel gene therapy strategy, which is able to protect normal tissue, particularly liver tissue, from the side effects of TRAIL expression is required.

Differential microRNA (miRNA) expression levels have been revealed between osteosarcoma and normal cells (9). A decrease in the expression of certain miRNAs enables the selective expression of inserted genes in osteosarcoma cells by their miRNA response elements (MREs). For example, miR-34 has been demonstrated to be underexpressed in osteosarcoma cells (10) and miR-122 is as a liver-enriched miRNA that can be used to suppress the expression of TRAIL in liver cells and thus minimize hepatotoxicity (11). However, to the best of our knowledge, the effectiveness of MRE-based gene therapy for the treatment of osteosarcoma has not yet been investigated.

In the present study, MREs of miR-34 and miR-122 were used to regulate the expression of TRAIL in order to confer its expression with osteosarcoma selectivity. Multidisciplinary experiments were performed to verify its effectiveness.
Materials and methods

Ad construction. Ad-enhanced green fluorescent protein (EGFP) and Ad-TRAIL were provided by Dr Zhao (Department of Urology, General Hospital of Chengdu Military Area Command of Chinese PLA, Chengdu, China). Ad-TRAIL-34-122 was constructed as follows: A DNA fragment containing two copies of the MREs of miR-34 and miR-122 (5'-GCCCGATATCCAACACCCACTGCCCACA A CACCCACTGCCCACAACACCCACACTCCCAAAAACCACAC TCCGATATCGGC-3') was synthesized and released from the temporary vector by EcoRV. The fragment was then inserted into pShuttle-cytomegalovirus (CMV)-TRAIL at the same site to obtain pShuttle-CMV-TRAIL-34-122. Subsequently, pShuttle-CMV-TRAIL-34-122 and pAdEasy were cotransfected into human embryonic kidney (HEK)293 cells (MicrobiX Biosystems, Mississauga, ON, Canada). The adenoviral vectors were purified using a CsCl centrifugation method (30,000 x g, 2.5 h), following identification by reverse transcription quantitative polymerase chain reaction (RT-qPCR). The titers of Ad-EGFP, Ad-TRAIL-34-122 and Ad-TRAIL were determined using a TCID<sub>50</sub> method on HEK293 cells and presented as pfu/ml.

Cell line cultures. The human osteosarcoma cell lines, KHOS, HOS, SaOS2, U2OS and MG-63 and the human normal lung fibroblast cell lines, NHLF and MRC5, were all purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Normal liver cells, L-02, were obtained from Shanghai Cell Collection (Shanghai, China). The cells were cultured using the recommended media (ATCC-formulated Eagle’s minimum essential medium for KHOS, HOS, MG-63, NHLF, and MRC5; ATCC-formulated McCoy’s 5a medium modified for Saos-2; Dulbecco’s modified Eagle’s minimum essential medium for U2OS, and HEK-293; RPMI-1640 medium for L-02 (Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 4 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all Invitrogen) at 37°C and 5% CO<sub>2</sub> in a humidified atmosphere.

RT-qPCR. For the detection of miR-34 and miR-122, fresh osteosarcoma samples were obtained from surgery (Department of Emergency Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China). Total RNA was extracted from 10 cancerous samples and corresponding normal tissues using TRIzol solution (Sigma-Aldrich, St. Louis, MO, USA) and pooled as one group for subsequent experiments. In addition, the KHOS, HOS, SaOs2, U2OS, MG-63, NHLF, MRC5 and L-02 cells were subjected to RNA extraction using TRIzol. The data were processed using REST 2009 software (Qiagen, Hilden, Germany).

The procedure used to detect TRAIL mRNA in the Ad-TRAIL-34-122-infected cells was as follows: In each well of 24-well plates, 4×10<sup>4</sup> cells were seeded. These cells were infected with Ad-TRAIL or Ad-TRAIL-34-122 with a multiplicity of infection (MOI) of 10. After 48 h, total RNA was extracted using TRIzol® solution (Invitrogen Life Technologies, Carlsbad, CA, USA), followed by cDNA generation by reverse transcription using a ReverTra Ace qPCR RT kit (Toyobo Co., Ltd., Osaka, Japan) according to the manufacturer’s instructions. Subsequently, SYBR premix Ex Taq (Takara Bio, Inc., Otsu, Japan) was used for RT-qPCR. The primers used for TRAIL detection were as follows: TRAIL, forward: 5'-GACCTGCGTGCTGATC-3' and reverse: 5'-TAAAAGAAGATGACAG-3'.

Luciferase assay. A DNA fragment, containing two copies of the miR-34 and miR-122 MREs (5'-GCCCTCGAGAACAAC CAGCTAACAGACTGCCAACACACAGCTAAGA -CACTGC CAAACACCATTGTCAACTCCACAACACCATTTG CAACACTCCAGCGGCCGCGGC-3'), was synthesized and inserted into a psiCheck2 vector at the sites XhoI and NotI (Promega Corporation, Madison, WI, USA) in order to generate psiCheck2-34-122.

Cells (4×10<sup>4</sup>) were cultured in each well of a 24-well plate. psiCheck2-34-122 and psiCheck2 were transfected into the cells using Lipofectamine 2000 (Invitrogen Life Technologies) and, 48 h later, these cells were treated with lysis buffer (Promega Corporation). The luciferase activities were then evaluated using a Dual-Luciferase reporter system kit (Promega Corporation).

Immunoblot assay. The total proteins were extracted using an M-PER<sup>®</sup> Mammalian Protein Extraction reagent (Thermo Fisher Scientific, Rockford, IL, USA) and then separated on 10% SDS-PAGE gels (Thermo Fisher Scientific). Subsequently, the proteins were transferred onto 0.45 µm nitrocellulose membranes (Thermo Fisher Scientific) and 5% fat-free dry milk was added to block the membrane. After 1 h, the membranes were incubated with the primary antibodies for 12 h at 4°C: Monoclonal rabbit anti-TRAIL, monoclonal rabbit anti-cle-PARP, monoclonal rabbit anti-cle-caspase 3, and monoclonal mouse anti-GAPDH. On day 2, the membranes were then incubated with the matched polyclonal goat anti-mouse or anti-rabbit immunoglobulin G secondary antibodies for 1 h at room temperature and the blots were detected using SuperSignal West Dura Extended Duration substrate (Thermo Fisher Scientific). All the above antibodies were all purchased from Cell Signaling Technology (Boston, MA, USA).

TRAIL determination by ELISA. To determine the concentration of secreted TRAIL, ELISA was performed. A total of 3.5×10<sup>4</sup> cells were cultured in each well of a 6-well plate and different adenoviral vectors (10 MOI) were added. After 48 h, sandwich ELISA (Thermo Fisher Scientific) was used to detect the expression level of TRAIL secreted into the media. The following antibodies were used: Monoclonal mouse TRAIL antibody and polyclonal goat TRAIL antibody (R&D Systems, Inc.) Absorbance was measured at a wavelength of 450 nm using a Microplate Reader (model 550; Bio-Rad Laboratories).

miRNA mimics and inhibitors. The mimics and inhibitors for miR-34 and miR-122 as well as the control mimics and
inhibitors were purchased from GenePharma (Shanghai, China). Prior to subsequent experiments, the indicated cells were transfected with the control mimic (200 nM) or a mixture of the miR-34 mimic (100 nM) and the miR-122 mimic (100 nM).

**Determination of apoptotic rates.** The cells (2x10^5) were cultured in 6-well plates. After 24 h, the indicated adenoviruses (10 MOI) were added to the media and, after 48 h, the cells were processed using an Annexin V-PE Apoptosis Detection kit (BioVision, Inc., Milpitas, CA, USA) according to the manufacturer's instructions. The apoptotic rate was then determined using flow cytometry.

**Cell viability assay.** The cells (1x10^5) were cultured in each well of a 96-well plate. The cells were infected with the indicated adenoviral vector of different MOI. After 6 days, 50 µl dimethyl sulfoxide (DMSO) was added to the cell media for 4 h incubation, and then the media was discarded and 150 µl DMSO was added. The 570 nm absorbance in each well was then assessed using a microplate reader (Model 550; Bio-Rad Laboratories) with a reference wavelength of 655 nm. Cell viability was calculated using the following formula: Cell viability (%) = absorbance value of infected cells - background absorbance / absorbance of uninfected control cells - background absorbance.

**Animal experiments.** The protocols of animal experiments were approved by the Experimental Animal Ethics Committee of Zhengzhou University.

To establish osteosarcoma xenografts, 2x10^6 KHOS cells were injected into the left flanks of 5-week-old BALB/c nude mice. A total of 24 mice were divided equally into four groups (n=6), once the tumor diameter reached 7-9 mm. Needles were used to intratumorally inject 100 µl PBS either with or without 2x10^8 pfu Ad-EGFP, Ad-TRAIL or Ad-TRAIL-34-122 five times every other day. The total dosage of adenoviruses reached 1x10^9 pfu. Calipers were used to periodically measure the tumor diameters. Tumor volume was then calculated using the following formula: Tumor volume (mm^3) = maximal length (mm) x perpendicular width (mm)^2 / 2.

**Liver function evaluation.** Female BALB/c mice (n=5) were intravenously administered with Ad-EGFP, Ad-TRAIL or Ad-TRAIL-34-122 (1x10^8 pfu) five times every other day, in order to determine the resulting hepatotoxicity. After 10 days, 600 ml serum was obtained from each mouse by cardiac puncture and then incubated with hepentin (12 U). Serum alanine aminotransferase (ALT) was subsequently quantified at the Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University.

**Histological staining.** A single mouse from each group was sacrificed 7 days after adenovirus administration. The tumor and liver tissues were fixed using formalin followed by histological staining based on the streptavidin biotin peroxidase complex method. TRAIL protein expression and distribution were determined using the TRAIL antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Prior to observation, the sections were counterstained with hematoxylin.

**Statistical analysis.** A two-tailed Student's t-test was used for statistical analysis in the present study. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Levels of miR-34 are reduced in osteosarcoma.** To confirm the downregulation of miR-34 in osteosarcoma, the miRNA expression profiles were examined in 10 samples of osteosarcoma. RT-qPCR indicated that the expression levels of miR-34 were decreased in osteosarcoma, compared with the corresponding normal tissue (P<0.01; Fig. 1A). Furthermore, the abundance of miR-34 was quantified in several osteosarcoma cell lines and levels were also found to be reduced in the cell lines assessed (Fig. 1B). The differential expression profile of miR-34 suggested that the application of these miRNAs regulated the expression of exogenous genes in the osteosarcoma cells.

**Application of miR-34 and miR-122 MREs regulates the expression of TRAIL in an osteosarcoma-selective manner.** To investigate whether the MREs of miR-34 and miR-122 can be applied for osteosarcoma-specific expression of exogenous genes, psiCkck2-34-122 U, a luciferase reporter vector regulated by the MREs of miR-34 and miR-122, was constructed (Fig. 1C). The results demonstrated that luciferase activity was not significantly affected in the psiCkck2-34-122-transfected osteosarcoma cells. However, its activity was markedly suppressed in the normal cell lines (Fig. 1D).

**MREs of miR-34 and miR-122 restrict the expression of TRAIL mediated by adenoviral vectors within osteosarcoma cells.** To confirm whether the application of miR-34 and miR-122 MREs enabled the selective expression of TRAIL in osteosarcoma cells, an adenoviral vector was constructed by inserting two copies of the miR-34 and miR-122 MREs at the end of the TRAIL-encoding sequence (Fig. 2A). The RT-qPCR assay revealed no difference in the expression of TRAIL between the Ad-TRAIL-34-122 and Ad-TRAIL-infected osteosarcoma cells (Fig. 2B). By contrast, Ad-TRAIL-34-122 suppressed the expression of TRAIL protein in normal cells (Fig. 2B). Immunoblotting and ELISA further demonstrated that Ad-TRAIL-34-122 treatment led to the selective expression of TRAIL in osteosarcoma cells, but not in the normal cells, infected with miR-34 mimics or miR-122 mimics (Fig. 2C and D). To confirm that TRAIL expression was regulated by the abundance of endogenous miR-34 and miR-122, the inhibitors or mimics of these miRNAs were added to the cell cultures. The data demonstrated that increasing the abundance of miR-34 and miR-122 in osteosarcoma cells led to a reduction in the expression of TRAIL proteins, while suppression of miR-34 and miR-122 by inhibitors resulted in the restoration of TRAIL in normal cells (Fig. 2E).

**Selective apoptosis in osteosarcoma cells is induced by miRNA-regulated expression of TRAIL.** As TRAIL initiates apoptosis in a wide range of cells, the present study investigated the activation of the apoptotic pathway in osteosarcoma and normal cell lines. Flow cytometric analysis of apoptotic rates revealed that apoptosis occurred specifically in the osteosarcoma cells, but not in the normal cells, infected with miR-34 mimics or miR-122 mimics (Fig. 2C and D). To confirm that TRAIL expression was regulated by the abundance of endogenous miR-34 and miR-122, the inhibitors or mimics of these miRNAs were added to the cell cultures. The data demonstrated that increasing the abundance of miR-34 and miR-122 in osteosarcoma cells led to a reduction in the expression of TRAIL proteins, while suppression of miR-34 and miR-122 by inhibitors resulted in the restoration of TRAIL in normal cells (Fig. 2E).
Ad-TRAIL-34-122 (Fig. 3A). By contrast, Ad-TRAIL induced apoptosis in osteosarcoma and normal cells (Fig. 3A).

Furthermore, immunoblot assays were also employed to confirm the activation status of the apoptotic pathway in osteosarcoma cells infected with TRAIL-expressing adenoviruses. Caspase-3 and poly ADP-ribose polymerase were found to be markedly cleaved in the Ad-TRAIL and Ad-TRAIL-34-122-transduced osteosarcoma cells and in the Ad-TRAIL-infected normal cells. However, no cleavage was observed in the normal cells infected with Ad-TRAIL-34-122 (Fig. 3B).

Ad-TRAIL-34-122 compromises the viability of osteosarcoma cells without significant cytotoxicity to normal cells. MTT assays were subsequently performed to determine the suppressive effect of Ad-TRAIL and Ad-TRAIL-34-122 on osteosarcoma cells and normal cells. According to the data, the viability of the osteosarcoma cells was inhibited when Ad-TRAIL and Ad-TRAIL-34-122 were added to the cell culture (Fig. 4A and B). However, the effect of Ad-TRAIL and Ad-TRAIL-34-122 on normal cells differed. Ad-TRAIL reduced the survival of normal cell lines, whereas their viability was not affected by Ad-TRAIL-34-122 (Fig. 4C and D).

TRAIL expression suppresses the growth of osteosarcoma xenografts in vivo. Subsequently, the effect of Ad-TRAIL-34-122 on the growth of osteosarcoma xenografts in mice was investigated. KHOS cells were used to establish the osteosarcoma xenografts. Mice were then intravenously injected with PBS, Ad-EGFP, Ad-TRAIL and Ad-TRAIL-34-122 and the tumor diameter was periodically measured. The data revealed that Ad-TRAIL and Ad-TRAIL-34-122 suppressed KHOS tumor growth in mice (Fig. 5A). The expression of TRAIL was also confirmed in the tumor sections using immunohistological staining (Fig. 5B).

Ad-TRAIL-34-122 exhibits no hepatotoxicity in mice. Finally, the present study investigated whether these adenoviral vectors led to hepatotoxicity in mice. PBS, Ad-EGFP, Ad-TRAIL and Ad-TRAIL-34-122 were injected into the tail vein of tumor-free BALB/c mice. The blood was harvested for analysis of serum ALT levels. The results revealed that Ad-TRAIL induced significant hepatotoxicity, evidenced by the elevated levels of ALT in the blood. However, Ad-TRAIL-MRE-34-122 did not alter the levels of ALT in the blood (Fig. 5C). Furthermore, immunohistological staining indicated that TRAIL was not expressed in the liver tissues from the mice injected with Ad-TRAIL-34-122 (Fig. 5B).

Discussion

The present study initially verified that the expression of miR-34 and miR-122 was underexpressed in osteosarcoma compared with in normal tissues. These results were consistent with a previous study (10). The difference in the levels of miR-34 and miR-122 between cancer and normal tissues suggested that the application of their MREs may confer the expression of inserted genes with specificity.

Further investigation using a luciferase reporter revealed that the MREs of miR-34 and miR-122 were able to suppress
exogenous gene expression in the normal cells rather than in the osteosarcoma cells. This effect of MREs on the expression of inserted genes has been confirmed in other types of cancer (12,13).

As expected, Ad-TRAIL-34-122 suppressed the viability of osteosarcoma cells by activating the apoptotic pathway and had no significant effect on the survival of normal cells, indicating high tumor selectivity. The use of MREs of tumor suppressor
Figure 4. Ad-TRAIL-34-122 reduces the viability of osteosarcoma without significant cytotoxicity to normal cells. Viability was determined in (A) MRC5, (B) L-02, (C) KHOS and (D) U2OS cells following application of the indicated adenoviruses. The absorption values of the cells without adenovirus infection were used as standards. Data are expressed as the mean ± standard error of the mean of three independent experiments. Ad, adenovirus; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; EGFP, enhanced green fluorescent protein; MOI, multiplicity of infection.

Figure 5. Ad-TRAIL-34-122 suppresses the growth of osteosarcoma xenografts in mouse models without hepatotoxicity. (A) Different adenoviruses (1x10^9 pfu) were intratumorally injected into mice bearing KHOS tumors and the tumor volumes were periodically measured. Data are expressed as the mean ± standard error of the mean of the tumor sizes. (B) Histological staining was performed to detect the expression of TRAIL in tumor and liver sections from the KHOS tumor-bearing mice and the tumor-free mice, respectively, following treatment with PBS, Ad-EGFP, Ad-TRAIL and Ad-TRAIL-34-122. Representative images are presented (magnification, x200). (C) ALT levels were detected in mice bearing no tumors following injection of different adenoviruses. Data are expressed as the mean ± standard error of the mean of ALT serum levels. PBS, phosphate-buffered saline; Ad, adenovirus; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; EGFP, enhanced green fluorescent protein; ALT, alanine aminotransferase.
miRNAs, including TRAIL, to regulate exogenous expression, mediated by adeno-viral vectors, has been assessed in bladder cancer and glioma (13,14). The therapeutic effect has been further verified in mice (13,14).

In addition to TRAIL, certain cytokines can also be used in MRE-regulated gene therapy for osteosarcoma, including dickkopf-1 and interleukin-24 (15,16). Furthermore, adeno-viral vectors from other serotypes are also suitable for MRE-regulated TRAIL therapy (15,17) due to their improved infectivity towards cancer cells.

In the present study, an MRE-regulated adenoviral vector that selectively expressed TRAIL in osteosarcoma cells was constructed. The results confirmed that this strategy was effective and safe and demonstrated that this miRNA-based anti-tumor gene therapy may be promising for the treatment of osteosarcoma.

References